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Abstract
Bipolar disorder is a chronic neuropsychiatric condition associated with mood instability, where patients present significant
sleep and circadian rhythm abnormalities. Currently, the pathophysiology of bipolar disorder remains elusive, but treatment
with lithium continues as the benchmark pharmacotherapy, functioning as a potent mood stabilizer in most, but not all
patients. Lithium is well documented to induce period lengthening and amplitude enhancement of the circadian clock. Based
on this, we sought to investigate whether lithium differentially impacts circadian rhythms in bipolar patient cell lines and
crucially if lithium’s effect on the clock is fundamental to its mood-stabilizing effects. We analyzed the circadian rhythms of
bipolar patient-derived fibroblasts (n= 39) and their responses to lithium and three further chronomodulators. Here we show,
relative to controls (n= 23), patients exhibited a wider distribution of circadian period (p < 0.05), and that patients with
longer periods were medicated with a wider range of drugs, suggesting lower effectiveness of lithium. In agreement, patient
fibroblasts with longer periods displayed muted circadian responses to lithium as well as to other chronomodulators that
phenocopy lithium. These results show that lithium differentially impacts the circadian system in a patient-specific manner
and its effect is dependent on the patient’s circadian phenotype. We also found that lithium-induced behavioral changes in
mice were phenocopied by modulation of the circadian system with drugs that target the clock, and that a dysfunctional
clock ablates this response. Thus, chronomodulatory compounds offer a promising route to a novel treatment paradigm.
These findings, upon larger-scale validation, could facilitate the implementation of a personalized approach for mood
stabilization.
Introduction
Bipolar disorder (BD) is a chronic illness characterized by
recurrent episodes of abnormal mood. It affects 1–3% of the
population worldwide and is one of the major causes of
chronic disability [1, 2]. The first-line treatment is lithium,
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functioning as a potent mood stabilizer in most patients
[3–5]. Little is known about the molecular pathways that
cause BD, other than hypotheses that build on a range of
targets of lithium [6]. As a consequence, BD has been
difficult to model in vitro, thus hampering drug discovery.
One leading hypothesis is that lithium modulates circadian
gene expression, and thus the stabilization of sleep and
circadian rhythms might offer novel treatment paradigms.
Sleep and circadian rhythm disruption have been noted
in many neuropsychiatric disorders, including BD [7–9].
Virtually all aspects of mammalian physiology and behavior
display 24 h circadian rhythms, driven by a series of
transcriptional–translational feedback loops that yield cell-
autonomous rhythm generation. The core of this molecular
clock is composed of CLOCK and BMAL1, which regulate
the expression of their negative repressors Per (Period 1/2/
3) and Cry (Cryptochrome 1/2), thus forming a process that
repeats every 24 h [10]. Indeed, the comorbid nature of
sleep/circadian disruption and mood is now well established
[11–13]: Diagnostic and Statistical Manual of Mental Dis-
orders 5 now recognizes this as a diagnostic criterion for
manic and depressive episodes [14].
At the mechanistic level, genes such as Clock, Bmal1, and
Per, which are intimately involved in the generation and
regulation of circadian rhythms, have been linked to BD
[15, 16], and this is supported by mouse models. ClockΔ19
mutant mice, for example, in addition to displaying sleep
and circadian deficits (reduced sleep requirement and
increased circadian period), display mania-like behaviors
including reduced anxiety and depression-like behaviors, as
well as increased risk taking and hyperhedonia [17, 18].
Consistent with the ClockΔ19 mutant, Afh (After-hours)
mice which carry a mutation in the clock-gene Fbxl3 thereby
preventing Cry (1/2) degradation, display significantly
altered rhythms and a mania-like phenotype [19–21], further
reinforcing a strong link between period length and mood-
related behaviors, and by extension BD and clock genes.
The highly accessible nature of skin cells and their ability
to pass on circadian timing to daughter cells, make fibro-
blasts a valid and promising tool for assessing human cir-
cadian rhythmicity [22]. Previous use of healthy human or
murine cells have found that the molecular clocks within
fibroblasts provide an accurate indication of rhythms gen-
erated in vivo and by the SCN [23–25]. Previous clock-gene
luminometric analysis found the period to be elongated by
up to 25 min in BD patient cells [26]. A subsequent study
found that BD fibroblasts exhibited nonsignificant (40 min)
trends in period lengthening [27] (Table 1).
Alongside these circadian abnormalities in BD, several
mood stabilizers, including lithium, have an effect on the
clock [28–30]. Lithium has been shown to increase the
amplitude and period of circadian rhythms in a range of
organisms from plants to humans [31–34]. As the targets of
lithium are many and various downstream consequences
remain unknown, the mechanism by which lithium acts on
the circadian system may be an attractive target for mood
modulation. Further, recent evidence of lithium’s action on
the clock comes from effects on BD patient lymphoblastic
cell lines [35]. Two days after treatment, cells from lithium-
responsive patients (unlike those from nonresponsive
patients) demonstrated elevated expression of the core clock
components Bmal1, Per1, and Cry2, providing further
clinical insight into the effects of lithium.
Here we have analyzed the circadian rhythms and
chronomodulatory drug responses of BD patient-derived
fibroblasts. We sought to answer three questions: (1) does
lithium differentially impact circadian rhythms in different
patient cell lines; (2) is lithium’s effect on the clock
necessary for mood stabilization; and (3) what factors pre-
dispose individuals toward sensitivity to lithium. While
lithium remains the first-line drug for BD, clinical response
varies. Accordingly, polypharmacy is common, and often
therapeutically necessary. We hypothesized that patients
taking fewer medications do so because their circadian
clocks respond well to lithium treatment, whereas those that
need a greater number of medications have a circadian clock
that is less responsive to chronomodulation.
We found that BD patients exhibited a wide distribution
of period length. Those with longer basal circadian periods
took more medications overall and displayed attenuated
responses to lithium (as well as alternative validated
chronomodulators), implying that lithium differentially
impacts the circadian system and that efficacy is determined
by the patients underlying circadian phenotype. Further-
more, we show that drugs that phenocopy lithium’s
circadian response in patient fibroblasts elicit behavioral
alterations akin to those for lithium in mice, and that a
Table 1 Summary of previous fibroblast bioluminescence reporter
studies assessing molecular rhythmicity from healthy controls or
bipolar patients.
Subject n Gene Period (h) Publication
Control 19 Bmal1 24.5 ± 0.75 (s.d.) Brown et al. [23]
Control 28 Bmal1 24.5 ± 0.75 (s.e.m.) Brown et al. [25]
9 24.71 ± 0.38 (s.e.m.) Pagani et al. [24]
Control 11 Bmal1 24.77 ± 0.42 (s.e.m.) Pagani et al. [24]
8 24.46 ± 0.48 (s.e.m.) Pagani et al. [24]
Control 19 Per2 25.10 ± 0.20 (s.e.m.) McCarthy et al. [26]
BD 19 25.50 ± 0.20 (s.e.m.)a McCarthy et al. [26]
Control 12 Bmal1 25.50 ± 0.60 (s.d.) Bamne et al. [27]
BD 13 26.30 ± 1.20 (s.d.) Bamne et al. [27]
aIndicates a significant difference.
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dysfunctional clock grossly alters murine lithium-induced
behavioral responses, suggesting an intricate link between
the circadian clock and lithium therapy.
Patients and methods
Compounds and reagents
All reagents were from Sigma-Aldrich except where stated
otherwise. Nuclease-free water or sterile DMSO was used to
prepare the compounds.
Subject characteristics
The control subjects who donated fibroblasts had an average
age of 53.56 ± 3.18 years. The BD subjects had an average
age of 43.10 ± 1.97 years; 82% were diagnosed with BP-I
disorder, and 67% presented with psychotic symptoms. The
patients were further divided into those who were lithium-
treated (Li-T) and lithium-non-treated (Li-NT); 77% of the
patients were taking lithium at the time of the biopsy
(Table S1) for an average of 10 years (Table S2). Only 20%
of patients were on lithium alone. In the rest, an assortment
of additional drugs (up to six) had been added to control
mood instability. The drugs were divided into five classes
by indication (Tables S3, S4). Patients were taking on
average a combination of two or three compounds across
multiple drug classes; mood stabilizers and antipsychotics
were the medications most frequently reported.
Cell lines
BD patient-derived dermal fibroblasts (n= 39) and control
subject-derived dermal fibroblasts (n= 23) were obtained
from the StemBANCC consortia, who oversaw the collec-
tion and culturing of cells from 500 individuals under
standardized conditions. Fibroblasts were derived from 3
mm punch-skin biopsies, following informed consent in
accordance with StemBANCC ethics practice [36]. Biopsies
were plated in Advanced DMEM (ADMEM, ThermoFisher
Scientific, Waltham, Massachusetts, USA) with 10% Fetal
Bovine Serum (FBS) for outgrowth of fibroblasts, with
subsequent expansion for generating a banked frozen stock
in 10% DMSO at passage 2 in nitrogen vapor. This was
further expanded for functional studies, which were carried
out at passages 4–6.
Lentivirus production and cell-line generation
Mass production of Bmal1-Luc or Per2-Luc virus was
performed to infect fibroblasts with the same batch of len-
tivirus. HEK-293 cells were seeded in HYPERflasks
(Corning, Corning, New York, USA). The plasmid complex
included: 60.4 μg reporter plasmid; Per2 (gift from Qing-
Jung Meng Lab) [37] and Bmal1 (pABpuro-BluF was a gift
from Steven Brown (Addgene plasmid # 46824)), 40.25 μg
packaging (psPAX2 was a gift from Didier Trono Addgene
plasmid # 12260), 16.1 μg envelope plasmid (pMD2.G was
a gift from Didier Trono (Addgene plasmid # 12259), and
1 mL of PEI-25 kDa (1 mg/mL; Polyscience, Warrington,
Pennsylvania, USA) as the transfection reagent. Then, 16 h
post transfection, the cellular media (DMEM, Sigma-
Aldrich, St. Louis, Missouri, USA) was replaced with fresh
media and incubated at 37 °C for 48 h, as previously
described [38]. The viral supernatant was concentrated in a
Vivaspin 20 and quantified using a p24 ELISA (Takara Bio,
Paris, France).
Fibroblasts grown in 75 cm2 flasks were transduced with
a spinfection protocol. Briefly, 100,000 fibroblast cells to be
transduced were lifted with TrypLE (ThermoScientific) and
centrifuged with 200 µl virus (~MOI 20) at 3000 × g, 25 °C
for 99 min. Cells were then resuspended in viral medium
and incubated at 37 °C overnight prior to use.
Assessing circadian rhythms
Fibroblasts were cultured to confluence (~30,000 cells/
well) in 96-well white plates (Greiner Bio-One, Glouces-
tershire, UK) using ADMEM (ThermoScientific) contain-
ing 10% FBS and 1% penicillin–streptomycin. Cells were
synchronized with 200 nM dexamethasone, diluted in
serum-free medium for an hour and washed twice with the
same solution (ThermoScientific) before reconstituting
with serum-free medium containing 1× B27 (Thermo-
Scientific) and 400 μM luciferin (Gold Biotechnology, St.
Louis, Missouri, USA). Bioluminescence was recorded for
4 days in Tecan M200 Pro readers. Actimetrics MultiCycle
was used to determine the period and amplitude (baseline
subtracted 24 h running average of the raw luminescence
data smoothed over 8 h). For luminometric experiments
involving the 62 fibroblast cell lines, three technical
replicates per dose, per drug, were conducted once and
averaged.
Correlograms
The statistical program R generated correlograms which
portray the correlation coefficient using a Pearson’s
parametric correlation test from +1 to −1 in Fig. 1f. Blue
and red are indicative of a positive and negative correla-
tion respectively; a larger circle represents stronger cor-
relation. Significance was assessed using a two-tailed t
test (bottom left); top right indicates significance follow-
ing adjustments for multiple comparisons using the
Holm–Bonferroni test.
5254 H. R. Sanghani et al.
Animals
Wild-type male C57BL/6J (Envigo, Huntingdon, UK) and
male Cry1/2−/− mice (a kind gift from Patrick Nolan, MRC,
Harwell, UK) of 8–12 weeks of age were housed under 12
h:12 h LD cycles for 1 week. The Cry1/2−/− mice [39] were
maintained as a homozygous line in the C57BL/6J back-
ground with regular backcrossing. Animals were housed and
assessed in a randomized manner across treatment groups to
avoid effects associated with housing location or order of
treatments. All analyses were automated to remove user
involvement. Each experiment involving a particular treat-
ment group/genotype was performed on a cohort of the
indicated size on a single occasion. Sample sizes were
estimated based on evidence from publications and past
experiments within our laboratory. Wild-type mice were
injected intraperitoneally (i.p.) with either vehicle (n= 7),
200mg/kg LiCl (n= 6), 50 mg/kg nobiletin (NOB) (n= 7),
or 5 mg/kg CGS-15943 (CGS) (n= 7). An independent
experiment assessing the impact of 200 mg/kg LiCl on
Cry1/2−/− mice was also conducted (vehicle+/+: n= 6,
LiCl+/+: n= 7, vehicleCry1/2−/−: n= 8, LiClCry1/2−/−: n= 8).
One mouse from the wild-type LiCl group and one mouse
from the vehicle group were excluded due to in-cage fighting.
The drugs were diluted in 0.9% NaCl with 5% kolliphor HS
15 and 5% 2-hydroxypropyl-β-cyclodextrin, except for LiCl,
which was diluted in 0.9% NaCl. Compounds were admi-
nistered for 10–12 days. The lithium dosage (200 mg/kg) was
Fig. 1 Lentivirus-transduced BP patient fibroblasts express a
variable underlying circadian phenotype. a Protocol to assess cir-
cadian rhythmicity. b Bmal1-Luc period differences between control
(n= 23) or BD patient (n= 39) fibroblasts were analyzed using two-
tailed Student’s t test with Welch’s correction, enabling variance
analysis. c Example oscillations from control and BD cells transduced
with the Bmal1-Luc lentivirus. d Linear regression comparing Bmal1-
Luc rhythms with Per2-Luc rhythms in BD patient-derived fibroblasts
(n= 18) reveals a correlation (R2= 0.621). e Comparison between BP-
I and BP-II cellular rhythms. f Correlogram revealing correlative
patterns and their significance using a Pearson parametric correlation
test on a scale of +1 to −1. Blue indicates positive correlation; red for
negative correlation; larger circles represent stronger correlation.
Results from a Student’s t test are presented in the bottom left
triangle, where the top right indicates significance following the
Holm–Bonferroni test. Data are mean ± s.e.m. *p < 0.05.
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chosen based on previous studies [40]. All procedures were
performed in accordance with the UK Home Office Animals
(Scientific Procedures) Act 1986 and the University of
Oxford’s and NC3R’s policy on the Use of Animals in Sci-
entific Research.
Open field test
The open field test (OFT) was performed using the Linton
AM1053 X, Y, Z IR Activity Monitor (San Diego Instru-
ments, San Diego, California, USA). Animals were assessed
in clear Perspex cages (36 × 20 × 15 cm) consisting of two
parallel frames of 24 equally spaced beams along the X and
Y (8 × 16) axis. Animal activity was scored in 1 min time
bins for 20 min.
Elevated plus maze
The elevated plus maze (EPM) utilized a maze elevated 47
cm off the ground. The apparatus consisted of a central
platform (5 × 5 cm) with two opposing open arms (28 × 5
cm) lit to 290 lux and two opposing close arms (28 × 5 × 30
cm, 50 lux). Each mouse was placed on the central platform
facing the closed arms and animal activity was recorded for
10 min. Video analysis was performed using ANY-maze
5.3 (Stoelting Co., Wood Dale, Illinois, USA). Mice that
fell or jumped off the EPM apparatus were excluded from
further analysis as these experiments were performed
without the user being present in the room.
Forced swim (Porsolt) test
The forced swim test (FST) was performed in a glass
cylinder (18 cm diameter, 27 cm height) filled with 3.5 L
water (24 ± 1 °C), a depth at which the animal’s tail is
unable to touch the bottom of the apparatus. Each mouse
was kept in the water for 6 min before being dried in a clean
cage and returned to the home cage. The water was changed
after each subject. Video analysis was performed using
ANY-maze 5.3.
Data analysis
Statistical analysis was performed using GraphPad Prism;
the results are presented as average ± s.e.m. The threshold
for significance was p < 0.05. An unpaired two-tailed t test
or welches t test was performed when comparing two
parameters. A one-way ANOVA with a Tukey or Dunnett’s
post hoc test was used when comparing multiple para-
meters. A two-way ANOVA with a Tukey or Sidak’s post
hoc test was applied when two independent variables were
present.
Results
The underlying circadian phenotype in BD
In order to perform luminometric recordings and analysis of
circadian rhythms in vitro, fibroblasts from BD patients and
controls were transduced with lentivirus where luciferase
expression was driven by activity at the Bmal1 or Per2
promoter regions (Fig. 1a). Following the creation of stable
cell lines, the fibroblasts were synchronized with 200 nM
dexamethasone, and basal period length was analyzed.
Both BD and control cells exhibited a normally distributed
period, but the BD cohort presented with a larger distribu-
tion and significantly greater variance, detected using the
Welch’s correction (control period: 21.69–25.64 h; BD:
20.19–26.45 h; p= 0.039) (Fig. 1b). We saw no difference
in basal period in BD patients compared with the controls
(control: 24.03 ± 0.20 h, BD: 23.87 ± 0.21 h) (Fig. 1b, c). To
validate this observation, an additional study with Per2 gene
expression was performed on a cellular subset (Fig. S1A, B),
and similar observations were obtained (control: 23.48 ±
0.27 h, bipolar: 23.93 ± 0.23 h). Regression analysis to
assess the correlation between Bmal1 and Per2 biolumi-
nescence rhythms (Fig. 1d) yielded a positive correlation
(R2= 0.621); patients with longer Bmal1 molecular rhythms
were more likely to display longer Per2 rhythms.
We explored whether known demographic characteristics
were responsible for the period variability within our BD
subject cell lines. BD and control cells displayed similar
growth rates (Fig. S1C). Furthermore, sex, age, the presence
of psychotic symptoms, and other key features analyzed
presented with no significant basal differences
(Fig. S1D–H). Interestingly, the emergent trend (Fig. 1e)
suggested that patients diagnosed with bipolar II disorder
(BP-II—who experience hypomania, and depression is
more prominent) had a period that was on average 1.1 h
shorter than those with bipolar I disorder (BP-I—mania is
more prominent) (BP-I: 24.05 ± 0.19, BP-II: 23.00 ± 0.74 h;
p= 0.054) [14]. This was the only parameter that approa-
ched significance in accounting for the variability observed
(Fig. 1b).
We next explored the emergent correlations between
circadian rhythms and treatment regime for the BD data in
the Per2 and Bmal1 regression analysis in Fig. 1d, f. We
detected a relationship between periodicity and medication:
patients with a shorter circadian period were taking more
mood stabilizers. By contrast, patients with a longer period
were taking more hypnotics and anxiolytics. Furthermore,
the longer the circadian period, the greater the total number
of medications. Thus, this offered preliminary support for
our hypothesis that patients exhibiting longer basal periods
are less responsive to chronomodulation by lithium.
5256 H. R. Sanghani et al.
Patient stratification reveals circadian drug
responses to be a determinant of basal circadian
rhythms
Our regression analysis (Fig. 1f) highlighted that patients
with longer periods were taking more medications. Hence,
to test the hypothesis that patients with longer periods are
less sensitive to lithium-induced chronomodulation, patients
were divided into three categories (Fig. 2a, Fig. S2A) based
on period length: short (up to 23.49 h), medium
(23.50–24.99 h), and long (25.00 h or more), where period
difference between successive groups was on average 1.5 h.
Their responses to lithium were determined experimentally.
The drug responses from control (Fig. S2B, C) and BD
cells assigned to these categories exhibited a clear spectrum
of dose-dependent responses (Fig. 2b, Fig. S2D). Significant
differences were evident between dose and basal circadian
period: long cells displayed lower period lengthening
responses over 10–30mM relative to short and medium cells
(Fig. 2c). Lithium was found to be incapable of increasing
the period beyond 27 h, regardless of the basal period. This
attenuated period increase in patients with longer periods
implies a plateau response in the case of lithium. Never-
theless, the altered lithium’s dependence on the basal cir-
cadian period (even when not approaching 27 h) suggests a
defect in the mechanism underpinning the clock machinery.
In contrast, amplitude enhancement was uniformly observed
(Fig. 2d) across all patient subgroups and lithium con-
centrations (Fig. 2d), thus demonstrating clear differences in
lithium’s effects on period and amplitude. A differential
effect of lithium—affecting one property of the clock
without affecting the other has not been described. This
provides compelling support for the notion that these two
properties are controlled independently [34]. Thus, as
hypothesized, differences in lithium-induced period length-
ening are determined by the underlying circadian phenotype.
To determine whether these differential chron-
omodulatory responses are unique to lithium or a general
circadian response of long-phenotype patients, two addi-
tional compounds were assessed: nobiletin (NOB), a poly-
methoxylated flavone [41] and CGS-15943 (CGS), a
nonspecific adenosine antagonist [42]. These function via
different primary targets and pathways, but show lithium-
like phenotypic effects on the clock.
NOB preferentially increased period in our short-period
fibroblasts at 10–30 μM, by up to 1.5 h (Fig. 2e). All cate-
gories presented amplitude enhancement, much as for
lithium. Whilst no effect for basal period was identified, the
clear and identifiable trend was that of muted amplitude
enhancement within long-period cell lines (Fig. 2f).
Therefore, NOB displayed trends for reduced chron-
omodulatory effects in long-phenotype patient cells similar
to lithium.
Unlike lithium, CGS induced period lengthening across
all categories. Cells derived from patients within the short,
medium, or long category displayed maximal period
lengthening by up to 12.6, 11.3, and 10.9 h (Fig. 2g),
consistent with the trend for long-phenotype displaying
muted responses. This further demonstrates that the
observed ceiling of lithium’s period increasing effect
(~27 h) is specific for lithium (Fig. 2c) rather than a
category-wide phenomenon, as seen with CGS (Fig. 2g–h).
Collectively, built on these observations we hypothe-
sized that the lack of lithium’s effect in long-period cells
was due to an inherent fault in the circadian network rather
than a ceiling effect. Therefore a drug capable of shortening
circadian period should demonstrate a similar divergent
effect across patient groups. Indeed, this proved to be the
case with 6-bromoindirubin-3′-oxime (BIO), a GSKβ inhi-
bitor that has previously been shown to shorten circadian
period (Fig. S2E, F) [34]. In a dose-response study con-
ducted with BIO, the short-period cells responded as pre-
dicted, with period shortening. In contrast the long-period
cells failed to demonstrate any shortening, in fact, they
responded with a mild period increase. Thus, along with
lithium, NOB, CGS, and BIO induced differential chron-
omodulatory responses conditional upon basal circadian
rhythms.
Fibroblasts’ lithium responses do not discriminate
between lithium-treated and non-treated patients
As our BD subject-derived cells were shown to display
patient-specific chronomodulatory responses to lithium, we
were curious to understand whether cells from lithium non-
medicated (Li-NT) patients would display any aberrant
pharmacological responses. Basal circadian period showed
no significant differences between the groups (Fig. 3a).
However, patients not taking lithium are not lithium non
responders, as patients can decline lithium for other reasons
(e.g., side effects, preference, or disbelief in the diagnosis).
Li-T and Li-NT cells displayed comparable period length-
ening in response to lithium (Fig. 3b); both groups con-
tained patients from the short, medium, and long categories.
Similarly, Li-T and Li-NT cells exhibited non-differential
dose-dependent amplitude enhancement (2.4-fold and 2.7-
fold, respectively) with 30 mM LiCl (Fig. 3c).
Nobiletin and CGS-15943 induce lithium-like
behavioral changes in rodents
Both NOB and CGS displayed lithium-like chron-
omodulatory changes dependent on the underlying basal
period (Fig. 2e–h). Importantly, the three compounds exert
their effects on the clock through different targets. We
therefore decided to assess whether these compounds
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induce similar behavioral modifications. If true, this would
suggest that pharmacological modulation of circadian
rhythm directly modulates affective behaviors, thus
providing the basis for a novel treatment paradigm. To
this end, we monitored two well-validated lithium-specific
behavioral changes [43]. Following acclimatization,
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wild-type C57BL/6J mice were administered i.p. injections
of LiCl, NOB, or CGS. After the final dose on day 12,
behavior was assessed using the OFT and EPM behavioral
methods (Fig. 4a).
Rearing activity was monitored using the OFT. Lithium
is well characterized to reduce rearing, an action indicative
of exploration and impulsivity [43]. We found that lithium
and NOB reduced the time spent rearing by 55 and 65%
respectively; nonsignificant (27%) reductions were
observed with CGS (Fig. 4b, c). In addition, mice treated
with lithium, NOB, and CGS reduced the number of central
rearing episodes by 75%, 63%, and 42% respectively
(Fig. 4d, e). The overall activity of animals confirmed that
our findings were not due to increased movement (Fig. 4f,
g). Therefore, it was concluded that NOB and CGS show
strong indications of lithium-like rearing behavior.
As lithium also modulates anxiety-related behaviors, we
tested behavioral responses on the EPM [43]. Mice treated
with LiCl, NOB, or CGS were more likely to enter the open
arms (2.7-, 2.5-, and 2.7-fold respectively; Fig. 4h), con-
firming that all three compounds possess anxiolytic-like
effects. Furthermore, mice treated with LiCl spent 4.5-fold
more time within the open arms; similarly, administering
NOB or CGS increased the time in the open arms by 3.7-
and 3.9-fold, respectively (Fig. 4i). Much like our findings
with the OFT, these compounds did not affect the amount of
time spent active (Fig. 4j). Therefore, as exemplified by the
tracking plots (Fig. 4k), NOB, and CGS phenocopied
lithium-induced behavioral modification.
Cry1/2−/− mice display atypical behavioral changes
with lithium treatment
To understand whether a dysfunctional clock is detrimental
for lithium treatment, we performed behavioral tests using
Cry1/2−/− mice. These mice have known circadian deficits,
including arrhythmicity, and reduced circadian amplitude
under constant conditions [44]. Thus, if the molecular clock
plays a part in mediating lithium’s effect, these should be
Fig. 2 The underlying patient-derived cellular circadian pheno-
type determines patient chronomodulatory responses to lithium,
nobiletin, and CGS-15943. a Patients were divided into groups based
on their basal Bmal1-Luc period length: short (23.49 h or less, n= 13),
medium (23.50–24.99 h, n= 17), and long (25.00 h or more, n= 9).
b 3D plot displaying the variable dose-dependent period change
induced by LiCl in 16 different BD patient cell lines. c Period and
d amplitude effects induced by 1–30 mM LiCl in short (n= 5),
medium (n= 6), or long (n= 5) BD fibroblasts. e, f Period and
amplitude changes induced by NOB in short (n= 5), medium (n= 6),
or long (n= 5) cells. g, h Chronomodulatory changes induced by CGS
in short (n= 5), medium (n= 6), or long (n= 5) fibroblasts. c–h Data
analysis was performed using a two-way ANOVA with a Tukey’s post
hoc test. Data are mean ± s.e.m. *p < 0.05; **p < 0.01; ***p < 0.001;
****p < 0.0001.












































































Fig. 3 Fibroblast lithium response do not discriminate between
lithium-treated and non-treated patients. a BD patients divided
according to lithium treatment; basal period differences analyzed using
a two-tailed Student’s t test. b Period and c amplitude effects induced
by LiCl in fibroblasts from Li-T (n= 10) and Li-NT patients (n= 6),
analyzed using a two-way ANOVA with a Sidak’s post hoc test. Data
are presented as mean ± s.e.m.
Patient fibroblast circadian rhythms predict lithium sensitivity in bipolar disorder 5259
altered in the Cry1/2−/− mice. Following i.p. injections of
LiCl, behavior was evaluated using the OFT, EPM, and
FST (Fig. 5a).
There were no overall OFT differences in the in active
time between lithium- and vehicle-treated animals (Fig. 5b,
c). As expected, lithium reduced central rearing behavior in
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wild-type mice by 65%; this was muted in Cry1/2−/− mice
along with total time spent rearing (Fig. 5d, e, Fig. S3A, B).
In the FST behavioral test (also known as a despair test),
lithium is known to increase the amount of time the animal
is active [43]. Wild-type mice treated with lithium displayed
a 34% reduction in immobility, whereas no significant
differences were observed for Cry1/2−/− mice (Fig. 5f, g;
Fig. S3C). In the EPM test, nonsignificant divergent trends
for increased frequency of open-arm entry and time spent in
the open arms were observed between these groups (Fig. 5h,
i, Fig. S3D). Importantly, lithium-altered behavioral
response has also been demonstrated with ClockΔ19 mice
[17]. Collectively, these data show that the typical lithium-
induced behavioral changes are significantly altered in mice
with dysfunctional clocks.
Discussion
Here we show that patient fibroblasts exhibiting a long-
period circadian phenotype exhibit atypical chron-
omodulatory responses to lithium. Crucially, we found that
this aberrant response extends to a range of chron-
omodulators that act via different molecular pathways, thus
suggesting a fundamental defect in the clock pathways.
Further, using circadian mutant mice we show that a func-
tional clock is required to exhibit typical lithium-mediated
behavioral responses. These data provide evidence to sug-
gest that patients with a dysfunctional circadian clock may
not exhibit typical clinical responses to lithium therapy.
Importantly, we also show that drugs that phenocopy
lithium at the cellular level elicit behavioral responses akin
to lithium in mice. Taken together, the results strongly
encourage the exploration of chronomodulation as a novel
route to achieving mood stability, with the potential to
translate into a new treatment paradigm for BD.
We could not confirm previous reports of longer circa-
dian cycles in fibroblasts from patients with BD using two
independent reporters. However, patients that exhibit a
wider distribution of circadian period lengths and longer
basal periods are associated with greater polypharmacy,
indicating possible lower effectiveness of lithium in these
patients. This is supported by the observation that longer
basal circadian periods are associated with muted responses
to chronomodulatory interventions with lithium. If lithium
differentially impacts the circadian system and its efficacy is
dependent on the patients’ underlying circadian phenotype,
this finding has important mechanistic and clinical impli-
cations. Pharmacological agents that modulated circadian
rhythmicity in vitro also induced lithium-like behavioral
changes in mice.
Using virally transduced Bmal1-Luc and Per2-Luc
subject-derived cells, we were unable to identify any sig-
nificant differences in basal period length. This is in contrast
to a previous study, which identified significant Per2 period
lengthening in BD by 25 min [26]. However, in accordance
with our investigation, no significant effects have been
observed with Bmal1-Luc-transduced fibroblasts or mRNA
analysis of patient cells [27, 45]. There are several reasons
why we believe our data provide an accurate representation
of the circadian state associated with BD. Firstly, the
StemBANCC consortia rigorously selected patients to cre-
ate a bio-bank for hard-to-treat disorders and thus fully
phenotyped patients for subsequent studies. Secondly, the
utilization of more patient cell lines (n= 39 in our study vs.
n= 12–19 in previous studies) may account for the wider
spectrum of periods associated with BD. Finally, the lack of
Bmal1 period lengthening in BD reported here is further
strengthened by our observation showing a similar lack of
period increase in BD using the Per2-reporter, further
validating these findings. Whilst it would be useful to
compare basal circadian amplitude between different patient
cell lines due to previous reports of BD patients demon-
strating muted amplitude, the number of viral integrations
per fibroblast dictates the observed basal amplitude in our
circadian assays. Thus, amplitude could simply be higher if
there were more copies of the Per2 or Bmal1 gene inserted
into the genome. However, basal period and drug-induced
period and amplitude changes are independent of the inte-
gration factor and were therefore our primary parameters.
The clinical features of the patients did not readily
explain the period variability observed within our BD
cohort. Whilst our control cohort had a balanced sex dis-
tribution (F:M, 55:45), the BD cohort had a female bias (F:
M, 74:26). Furthermore, the control cohort was on average
10 years older (BD 43 years vs. control 53 years). However,
given there was no correlation between age and sex with
basal circadian period or lithium response (Fig. S1) these
factors are unlikely to account for our observed differences.
Further, to take account of the variable sample numbers
between the control and BD cohort, we used Welch’s t test
which is better suited to handle variable sample sizes and
variances [46, 47]. Disease diagnosis showed that BP-II
patients had a shorter period than BP-I patients (by 1.1 h,
Fig. 4 Nobiletin and CGS-15943 as pharmacological modulators of
circadian rhythms mimic behavioral changes induced by lithium.
a C57BL/6J mice were administered (i.p.) vehicle (n= 7), LiCl (n=
6), NOB (n= 7), or CGS (n= 7) then subjected to OFT and EPM
behavioral tests. OFT: effects of compounds on (b, c) time spent
rearing, (d, e) normalized number of center rears with representative
traces, and (f, g) time spent active. EPM (1.5–2 h after the OFT):
effects of compounds on (h) number of entries into the open arm,
(i) time spent in the open arm, and (j) time spent active. k Repre-
sentative tracking plots. Blue and red dots indicate mice positions when
analysis began and ended, respectively. Data were analyzed using a
one-way ANOVA with a Dunnett’s post hoc test and are presented as
mean ± s.e.m. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
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p= 0.054). Although there are no reports directly compar-
ing cellular rhythmicity in BP-I vs. BP-II patients, differ-
ences in sleep have been identified, and sleep efficiency and
duration were improved only in BP-I patients taking lithium
[48]. However, due to the limited sample size, it would be
prudent to replicate this study with a larger cohort; if the
observation is validated, this could enable the identification
of appropriate chronomodulatory compounds in the future.
Our investigation confirms previous findings that lithium
induces period lengthening and increases amplitude
[28, 34, 49, 50]. Further, we report that patient cells with
longer circadian periods show reduced circadian responses
to lithium. We also demonstrate that this deficit applies to
other chronomodulatory compounds: CGS, NOB, and BIO
(both period increasing and decreasing modulators). As
CGS, NOB, and lithium function via distinct primary tar-
gets and cellular mechanisms (CGS: nonspecific adenosine
antagonist [42]; NOB: multiple targets, including retinoid
orphan receptor [41] and CREB [51]; lithium: multiple
targets e.g., IMPase, GSK3β [52]), such altered chron-
omodulatory effects in patient fibroblasts in response to
these drugs are unlikely to be mediated by changes in
activity associated with a single target. Rather, our obser-
vations point to a general mechanistic aberration in these
patients’ clocks and the chronomodulatory agents driving
the clock to an altered equilibrium to overcome these
functional deficits. Indeed, the specific observation that
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Fig. 5 Lithium treatment differentially modulates behavior in Cry1/
2−/− mice. a Wild-type and Cry1/2−/− mice were administered (i.p.)
vehicle or LiCl (vehicle+/+: n= 6, LiCl+/+: n= 7, vehicleCry1/2−/−: n=
8, LiClCry1/2−/−: n= 8) and tested by OFT, EPM, and FST. OFT effects
of lithium on (b), (d) time spent active and the normalized number of
center rears, with (c), (e) representative traces to visualize the treatment
and genotype differences in response to lithium. FST effects on
(f), (g) time spent immobile. h EPM number of entries into the open
arm. i Heat maps from representative mice highlighting behavioral
differences in the EPM. Data were analyzed using a two-way ANOVA
with a Sidak’s post hoc test and presented as mean ± s.e.m. *p < 0.05.
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recent study [53]. It is unlikely that the longer phenotype is
a consequence of long-term medication, as the cells were
passaged at least 4–6 times since biopsy, during which time
the drugs would have washed out, excluding potential epi-
genetic changes. Further, there was no difference in circa-
dian responses between Li-T and untreated cells. Whilst we
cannot conclude that control-subject derived fibroblasts
would not also show similar effects, such subjects would
never need to take lithium therapeutically. Therefore, our
primary focus was on understanding the lithium response
across BD patients. Overall, we show that drug responses
vary in BD patients based on the underlying cellular cir-
cadian rhythms. Thus, currently unidentified factors that are
implicated in the functioning of the molecular clock may be
significantly disrupted in patients with longer basal circa-
dian periods. If this can be validated on a larger scale, with
mood regulation as an additional outcome, patient-derived
fibroblasts could become a meaningful biomarker and
facilitate the implementation of a personalized approach to
lithium treatment. Whilst lithium’s established effects
require long-term therapy to become apparent, we show
almost immediate changes to circadian rhythms in our cell
model. It has been shown with several other mood mod-
ulators that even in the absence of measurable changes in
subjective mood, changes in emotional processing and
memory are apparent after a single treatment [54]. This
suggests that whilst the neurophysiological and mechanistic
changes induced by these therapeutics are almost immedi-
ate, their translation into improved symptoms exhibit a lag
[55]. Similarly to these agents, we hypothesize that bene-
ficial alterations to circadian rhythms will initiate neuro-
physiological changes and promote improvements in patient
symptoms.
Although screening for novel clock modulators has been
performed on immortalized cells [56–58], as we do not fully
understand BD, use of our patient-derived fibroblasts have
several advantages over existing models. Fibroblasts pro-
vide a more biologically relevant representation of the
individual’s genetic makeup, and they represent a valid
indication of human physiological circadian rhythmicity
(Table 1). This therefore provides researchers with a more
accurate model of the disease, which may help identify
patient-relevant pharmacological treatments in the future.
Furthermore, the patients from whom our fibroblasts origi-
nated were extensively evaluated: each cell-line was
accompanied by a wealth of long-term phenotypic infor-
mation. Therefore, all these 39 fibroblast lines could be
utilized in the future, or particular cell lines could be
selected based on the research needs or the genetics behind
the differential drug responses be explored. The creation of
a patient-derived fibroblast model also significantly reduces
the need for animals, including transgenic mice to model
circadian rhythm deficits in mood disorders; replacing
with a human relevant model will be highly beneficial at
various stages of drug discovery, including high-throughput
screening.
This investigation also found that the novel chron-
omodulatory drugs NOB and CGS reduce rearing and
anxiety-related behavior, similar to lithium. This supports
the theory that drugs that modulate circadian rhythm can
alter temperament. Indeed, several lines of study support
this; key examples include the fact that the melatonergic
agonist agomelatine and light therapy normalize extreme
behavioral irregularities such as depression, mania, and
delusions [59–62]. Furthermore, work in ClockΔ19 mice
has shown that lithium-induced behavioral responses are
altered in a range of behavioral tests including EPM, OFT,
and FST, thus yielding evidence for interactions between
lithium, the molecular clock, and behavior. To provide
further evidence that these effects are not specific to the
ClockΔ19 genotype, we performed comparable behavioral
experiments and showed that lithium’s effects are indeed
altered in Cry1/2−/− mice, compared with controls. Col-
lectively, these investigations provide evidence for the
involvement of the molecular clock in lithium’s behavioral
effects.
In conclusion, patient-derived fibroblasts enabled the
identification of differential drug responses based on basal
circadian rhythms. This advances our understanding of the
role of circadian rhythms in BD and supports the wealth of
evidence demonstrating a close relationship between circa-
dian rhythms and the pathophysiology of BD. If pharma-
cological modulation of circadian rhythms can provide a
novel method to achieve mood stability, it will be necessary
to validate these findings with additional molecules and in
larger studies in the hope of identifying a new treatment
paradigm for BD and perhaps other neuropsychiatric
disorders.
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